Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 3 spellings of its name, each linked to the record.
As of Nov 16, 2026, FDA's public records list Esperion Therapeutics with 2 drug applications, 2 drug recalls and 1 OPDP letter. The most recent is an OPDP letter dated Dec 19, 2025: Untitled letter: NEXLIZET.
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
A hatched bar is a year that is not over, so its count covers only part of the year.
| Dec 19, 2025 | Untitled letter: NEXLIZETOffice of Prescription Drug Promotion | OPDP letters |
| Mar 27, 2024 | NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor,Class III · Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint. | Drug recalls |
| Aug 16, 2023 | Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108,Class III · Failed dissolution specifications: below specification results at stability 12-month | Drug recalls |
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built